La Jolla Pharmaceutical Company (LJPC) saw its loss widen to $23.24 million, or $1.26 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $16.48 million, or $0.96 a share. The company has not recorded any revenues for the current quarter. However, it has reported a revenue of $0.23 million for the previous year period.
Operating loss for the quarter was $23.27 million, compared with an operating loss of $16.53 million in the previous year period.
“The first quarter of 2017 was an exciting time at La Jolla, highlighted by the positive top-line results from ATHOS-3,” said George Tidmarsh, M.D., Ph.D., president and chief executive officer of La Jolla. “We look forward to continuing a productive 2017, with the expected LJPC-501 New Drug Application submission in the second half of 2017."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
